Prof. Alberto Gabizon, MD, PhD - Shaare Zedek Medical Center and Hebrew University-School of Medicine - Professor of Medicine and Director of Oncology Institute

Prof. Alberto Gabizon

MD, PhD

Shaare Zedek Medical Center and Hebrew University-School of Medicine

Professor of Medicine and Director of Oncology Institute

Jerusalem | Israel

Additional Specialties: Oncology


Top Author

Prof. Alberto Gabizon, MD, PhD - Shaare Zedek Medical Center and Hebrew University-School of Medicine - Professor of Medicine and Director of Oncology Institute

Prof. Alberto Gabizon

MD, PhD

Introduction

Primary Affiliation: Shaare Zedek Medical Center and Hebrew University-School of Medicine - Jerusalem , Israel

Additional Specialties:


View Prof. Alberto Gabizon’s Resume / CV

Metrics

Number of Publications

65

Publications

Number of Profile Views

2621

Profile Views

Number of Article Reads

1204

Reads

Number of Citations

1215

Citations

Education

Dec 1979
Weizmann Institute of Science, Rehovot, Israel
PhD
Dec 1974
Faculty of Medicine, University of Granada, Spain
MD

Experience

Dec 1985
Israel Medical Council Board Certification
Specialist

Top co-authors

Hilary Shmeeda
Hilary Shmeeda

Shaare Zedek Medical Center

23
Tal Grenader
Tal Grenader

Shaare Zedek Medical Center

12
Dina Tzemach
Dina Tzemach

a Shaare Zedek Medical Center

11
Yasmine Amitay
Yasmine Amitay

Lipomedix Pharmaceuticals Ltd.

10
Yechezkel Barenholz
Yechezkel Barenholz

Laboratory of Membrane and Liposome Research

8
Lidia Mak
Lidia Mak

a Shaare Zedek Medical Center

7
Samuel Zalipsky
Samuel Zalipsky

ALZA Corporation

6
Patricia Ohana
Patricia Ohana

Lipomedix Pharmaceuticals Ltd.

6

Publications

65Publications

1204Reads

1215PubMed Central Citations

Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore.

Dalton Trans 2018 Jul;47(28):9283-9293

School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, SE1 7EH, UK.

View Article
July 2018
3 Reads
2 Citations
4.200 Impact Factor

Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).

Nanomedicine 2018 Apr 19;14(4):1407-1416. Epub 2018 Apr 19.

Hebrew University-School of Medicine, Jerusalem, Israel; Shaare Zedek Medical Center- Oncology Institute, Jerusalem, Israel; Lipomedix Pharmaceuticals Ltd., Jerusalem, Israel. Electronic address:

View Article
April 2018
4 Reads
6.160 Impact Factor

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.

J Control Release 2018 Feb 23;271:139-148. Epub 2017 Dec 23.

Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, School of Pharmacy, Abilene, TX, USA. Electronic address:

View Article
February 2018
15 Reads
1 Citation
7.700 Impact Factor

Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.

Mol Pharm 2017 12 30;14(12):4339-4345. Epub 2017 Oct 30.

Laboratory of Membrane and Liposome Research, The Hebrew University-Hadassah Medical School, IMRIC , Jerusalem, Israel.

View Article
December 2017
15 Reads
4.380 Impact Factor

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

Drug Resist Updat 2016 11 29;29:90-106. Epub 2016 Oct 29.

Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX, USA.

View Article
November 2016
17 Reads
6 Citations
9.120 Impact Factor

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.

Int J Radiat Oncol Biol Phys 2016 11 1;96(3):547-55. Epub 2016 Jul 1.

Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address:

View Article
November 2016
27 Reads
1 Citation
4.260 Impact Factor

MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing.

Anticancer Drugs 2016 07;27(6):569-72

aShaare Zedek Medical Center bSchool of Medicine, Hebrew University, Jerusalem, Israel cMemorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article
July 2016
14 Reads
1.890 Impact Factor

Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.

J Control Release 2016 Mar 22;225:87-95. Epub 2016 Jan 22.

Hebrew University-School of Medicine, Jerusalem, Israel; Oncology Institute at Shaare Zedek Medical Center, Jerusalem, Israel; Lipomedix Pharmaceuticals Ltd., Jerusalem, Israel. Electronic address:

View Article
March 2016
16 Reads
2 Citations
7.700 Impact Factor

A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.

J Control Release 2015 Jun 11;208:106-20. Epub 2015 Apr 11.

Department of Physiology and Pharmacology, Sackler School of Medicine, Room 607, Tel Aviv University, Tel Aviv 69978, Israel. Electronic address:

View Article
June 2015
17 Reads
4 Citations
7.700 Impact Factor

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.

Anticancer Drugs 2015 Mar;26(3):241-58

Oncology Institute, Shaare Zedek Medical Center and Hebrew University, School of Medicine, Jerusalem, Israel.

View Article
March 2015
26 Reads
21 Citations
1.890 Impact Factor

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses.

Nanomedicine 2015 Feb 6;11(2):259-62. Epub 2014 Sep 6.

Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX, USA. Electronic address:

View Article
February 2015
32 Reads
7 Citations
6.160 Impact Factor

Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.

Anticancer Drugs 2015 Jan;26(1):106-11

aDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York bInstitute of Heart, Vascular, and Stroke Care, Massachusetts General Hospital, Boston, Massachusetts, USA cBlood Bank and Hematology Laboratory, Shaare Zedek Medical Center dDepartments of Oncology and Hematology, Shaare Zedek Medical Center eFaculty of Medicine, Hebrew University, Hadassah School of Medicine, Jerusalem, Israel.

View Article
January 2015
19 Reads
1 Citation
1.890 Impact Factor

Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics".

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Oct 7.

Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel (NIC); Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (EGEdV); Kellog School of Management and Northwestern University Medical School, Chicago, IL (LE); Sussex Health Outcomes Research & Education in Cancer (SHORE-C),Brighton & Sussex Medical School, University of Sussex, Falmer, UK (LF); Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (PAF); Department of Oncology, Shaare Zedek Medical Center, and Hebrew University-School of Medicine, Jerusalem, Israel (AG); Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium (MJP); Department of Otolaryngology and Oncology, Johns Hopkins University, Baltimore, MD (DS); Oncotest/Verify, Teva Pharmaceutical Industries, Petach Tikva, Israel (LS-G); Melabev Community Elders Care Research Department, Jerusalem, Israel (CT).

View Article
December 2014
20 Reads
3 Citations
12.580 Impact Factor

Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.

J Immunol 2014 Dec 22;193(11):5557-66. Epub 2014 Oct 22.

King's College London, King's Health Partners Integrated Cancer Centre, London SE1 9RT, United Kingdom; Department of Immunology, Barnet Hospital, Barnet, Hertfordshire EN5 3DJ, United Kingdom; and Department of Clinical Immunology and Allergy, King's College Hospital National Health Service Foundation Trust, London SE5 9RS, United Kingdom

View Article
December 2014
62 Reads
13 Citations
4.920 Impact Factor

Cancer nanomedicines: closing the translational gap.

Lancet 2014 Dec 19;384(9961):2175-6. Epub 2014 Dec 19.

Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address:

View Article
December 2014
16 Reads
16 Citations
45.220 Impact Factor

Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.

Oncol Rep 2014 Jan 14;31(1):428-34. Epub 2013 Nov 14.

Department of Oncology, Shaare Zedek Medical Center, and Hebrew University-School of Medicine, Jerusalem, Israel.

View Article
January 2014
20 Reads
3 Citations
2.190 Impact Factor

Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?

Oncologist 2012 23;17(12):1534-40. Epub 2012 May 23.

NYU Clinical Cancer Center, 550 First Avenue, New York, NY 10016, USA.

View Article
June 2013
9 Reads
4.870 Impact Factor

Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.

J Control Release 2013 May 16;167(3):265-75. Epub 2013 Feb 16.

Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
May 2013
29 Reads
13 Citations
7.700 Impact Factor

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Cancer Res 2013 Apr 19;73(8):2412-7. Epub 2013 Feb 19.

Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, MD 20892, USA.

View Article
April 2013
14 Reads
230 Citations
9.330 Impact Factor

Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

World J Clin Oncol 2012 Oct;3(10):137-41

Tal Grenader, Ora Rosengarten, Rut Isacson, Yevgeni Plotkin, Alberto Gabizon, Department of Oncology, Sha'are Zedek Medical Center, Jerusalem 91031, Israel.

View Article
October 2012
22 Reads
1 Citation

Liposome imaging agents in personalized medicine.

Adv Drug Deliv Rev 2012 Oct 12;64(13):1417-35. Epub 2012 Sep 12.

Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Produktionstorvet 423, 2800 Lyngby, Denmark.

View Article
October 2012
8 Reads
24 Citations
15.040 Impact Factor

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.

J Control Release 2012 Jun 26;160(2):245-53. Epub 2011 Nov 26.

Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
June 2012
10 Reads
6 Citations
7.700 Impact Factor

Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.

Eur J Pharm Sci 2012 Mar 10;45(4):388-98. Epub 2011 Sep 10.

Oncology Institute, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel.

View Article
March 2012
9 Reads
15 Citations
3.350 Impact Factor

Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.

PLoS One 2011 6;6(10):e25721. Epub 2011 Oct 6.

Laboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.

View Article
February 2012
13 Reads
8 Citations
3.230 Impact Factor

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.

Cancer Chemother Pharmacol 2012 Jan 18;69(1):43-50. Epub 2011 May 18.

UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

View Article
January 2012
16 Reads
16 Citations
2.770 Impact Factor

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

Adv Drug Deliv Rev 2011 Sep 14;63(12):1020-30. Epub 2011 Jul 14.

Nanomedicine Research and Education Center, Bay Zoltan Foundation for Applied Research and Semmelweis University Medical School, Budapest, Hungary.

View Article
September 2011
28 Reads
38 Citations
15.040 Impact Factor

Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin.

J Clin Oncol 2011 Sep 25;29(25):e722-4. Epub 2011 Jul 25.

Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
September 2011
20 Reads
6 Citations
18.430 Impact Factor

Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?

Anticancer Drugs 2010 Oct;21(9):868-71

Department of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel.

View Article
October 2010
7 Reads
1 Citation
1.890 Impact Factor

Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.

J Control Release 2010 Aug 10;146(1):76-83. Epub 2010 May 10.

Experimental Oncology Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
August 2010
19 Reads
15 Citations
7.700 Impact Factor

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Cancer Chemother Pharmacol 2010 May 25;66(1):43-52. Epub 2009 Sep 25.

Experimental Oncology Laboratory, Shaare Zedek Medical Center, 11 Shmuel Bayit Street, 7th Floor, PO Box 3235, Jerusalem 91031, Israel.

View Article
May 2010
24 Reads
19 Citations
2.770 Impact Factor

What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?

J Clin Oncol 2010 Apr 1;28(12):e193-4; author reply e195-6. Epub 2010 Mar 1.

View Article
April 2010
9 Reads
1 Citation
18.430 Impact Factor

Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.

Anticancer Drugs 2009 Oct;20(9):845-7

Department of Oncology, Sha'are Zedek Medical Center, Jerusalem, Israel.

View Article
October 2009
12 Reads
4 Citations
1.890 Impact Factor

Ultrasound triggered release of cisplatin from liposomes in murine tumors.

J Control Release 2009 Jul 19;137(1):63-8. Epub 2009 Mar 19.

Department of Chemical Engineering, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.

View Article
July 2009
21 Reads
44 Citations
7.700 Impact Factor

Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.

J Control Release 2009 Jun 7;136(2):155-60. Epub 2009 Feb 7.

Experimental Oncology Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
June 2009
12 Reads
18 Citations
7.700 Impact Factor

Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.

Anticancer Drugs 2009 Jan;20(1):15-20

Department of aOncology bDiagnostic Radiology, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
January 2009
22 Reads
1.890 Impact Factor

Primary amelanotic melanoma of the vagina.

Onkologie 2008 Sep 12;31(8-9):474-6. Epub 2008 Aug 12.

Department of Oncology, Sha'are Zedek Medical Center, Jerusalem, Israel.

View Article
September 2008
15 Reads
2 Citations
0.840 Impact Factor

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.

Cancer Chemother Pharmacol 2008 Apr 5;61(4):695-702. Epub 2007 Jun 5.

Department of Oncology, Shaare Zedek Medical Center, POB 3235, Jerusalem, 91031, Israel.

View Article
April 2008
13 Reads
14 Citations
2.770 Impact Factor

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.

Clin Lymphoma Myeloma 2008 Feb;8(1):21-32

Oncology Department, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
February 2008
6 Reads
23 Citations

Significant drug interaction: phenytoin toxicity due to erlotinib.

Lung Cancer 2007 Sep 26;57(3):404-6. Epub 2007 Mar 26.

Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
September 2007
9 Reads
3 Citations
3.960 Impact Factor

Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.

Langmuir 2007 Mar 24;23(7):4019-25. Epub 2007 Feb 24.

Department of Chemical Engineering, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.

View Article
March 2007
8 Reads
29 Citations
4.460 Impact Factor

Pros and cons of the liposome platform in cancer drug targeting.

J Liposome Res 2006 ;16(3):175-83

Shaare Zedek Medical Center, Hebrew University Medical School, Jerusalem, Israel.

View Article
December 2006
13 Reads
39 Citations
1.820 Impact Factor

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

Endocr Relat Cancer 2006 Jun;13(2):535-40

Endocrinology and Metabolism Service, Department of Medicine, Hadassah University Hospital, P.O.B 12000, Jerusalem, Israel 91120.

View Article
June 2006
14 Reads
32 Citations
4.800 Impact Factor

Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors.

Mol Cancer Ther 2006 Apr;5(4):818-24

Experimental Oncology Laboratory, Shaare Zedek Medical Center, and Hebrew University-Hadassah Medical Schol, Jerusalem, Israel.

View Article
April 2006
25 Reads
20 Citations
5.680 Impact Factor

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.

Clin Cancer Res 2006 Mar;12(6):1913-20

Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
March 2006
12 Reads
8 Citations
8.720 Impact Factor

Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues.

Bioconjug Chem 2004 Jul-Aug;15(4):814-23

Department of Medicinal Chemistry and Natural Products, School of Pharmacy, P.O. Box 12065, The Hebrew University of Jerusalem, 91120, Israel.

View Article
January 2005
20 Reads
10 Citations
4.510 Impact Factor

Cardiac safety of liposomal anthracyclines.

Semin Oncol 2004 Dec;31(6 Suppl 13):161-81

University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article
December 2004
11 Reads
14 Citations
3.900 Impact Factor

Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.

Cancer Invest 2004 ;22(5):663-9

Oncology Institute, Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel.

View Article
December 2004
18 Reads
15 Citations
2.060 Impact Factor

Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.

Adv Drug Deliv Rev 2004 Apr;56(8):1177-92

Oncology Department, Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel.

View Article
April 2004
23 Reads
73 Citations
15.040 Impact Factor

Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies.

Bioconjug Chem 2003 May-Jun;14(3):563-74

Department of Medicinal Chemistry and Natural Products, School of Pharmacy, P. O. Box 12065, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.

View Article
January 2004
26 Reads
24 Citations
4.510 Impact Factor

In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

Clin Cancer Res 2003 Dec;9(17):6551-9

Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
December 2003
21 Reads
47 Citations
8.720 Impact Factor

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Clin Pharmacokinet 2003 ;42(5):419-36

Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
September 2003
34 Reads
195 Citations
5.050 Impact Factor

Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.

Anticancer Drugs 2003 Mar;14(3):247-50

Department of Radiology, Shaare Zedek Medical Center, Jerusalem, Israel.

View Article
March 2003
21 Reads
4 Citations
1.890 Impact Factor

Emerging role of liposomal drug carrier systems in cancer chemotherapy.

Authors:
Alberto Gabizon

J Liposome Res 2003 Feb;13(1):17-20

Shaare Zedek Medical Center and Hebrew University Hadassah Medical School, Jerusalem, Israel.

View Article
February 2003
10 Reads
2 Citations
1.820 Impact Factor

Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects.

J Drug Target 2002 Nov;10(7):535-8

Oncology Institute, Shaare Zedek Medical Center and Hebrew University-Hadassah Medical School, Jerusalem, Israel.

View Article
November 2002
5 Reads
5 Citations

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.

J Drug Target 2002 Nov;10(7):539-48

Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

View Article
November 2002
27 Reads
23 Citations

Top co-authors

Hilary Shmeeda
Hilary Shmeeda

Shaare Zedek Medical Center

23
Tal Grenader
Tal Grenader

Shaare Zedek Medical Center

12
Dina Tzemach
Dina Tzemach

a Shaare Zedek Medical Center

11
Yasmine Amitay
Yasmine Amitay

Lipomedix Pharmaceuticals Ltd.

10
Yechezkel Barenholz
Yechezkel Barenholz

Laboratory of Membrane and Liposome Research

8
Lidia Mak
Lidia Mak

a Shaare Zedek Medical Center

7
Samuel Zalipsky
Samuel Zalipsky

ALZA Corporation

6
Patricia Ohana
Patricia Ohana

Lipomedix Pharmaceuticals Ltd.

6